Low level of matrix metalloproteinase-1 in patients with bladder cancer and the effect of MMP-1 polymorphism (-1607) on serum MMP-1 levels and the risk of bladder cancer

WCRJ 2018; 5 (3): e1132

  Topic: Molecular biology     Category:

Abstract

Objective: Matrix metalloproteinases play an important role in the development and progression of cancerous tumors. The current study aimed at determining the genetic polymorphism in matrix metalloproteinase-1 (MMP-1) gene (rs1799750) and susceptibility to bladder cancer, evaluating serum MMP-1 level, and investigating the effect of the polymorphism on serum MMP-1 levels.
Materials and Methods: A total of 157 patients with bladder cancer and 143 healthy subjects were recruited. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was employed to determine genetic polymorphism. Serum MMP-1 level was measured by the enzyme-linked immunosorbent assay (ELISA) technique.
Results: The mean serum level of MMP-1 was 2.676 ±1.77 ng/mL in the patient group and 3.00 ±1.69 ng/mL in the control group. There was a significant decrease in serum MMP-1 level in the patient group compared with the control group. There was no significant association between MMP-1 polymorphism and susceptibility to bladder cancer. A three-fold higher risk of bladder cancer was associated with smoking.
Conclusions: The genetic variation in MMP-1 (–1607) polymorphism is not associated with the risk of bladder cancer. It seems that serum MMP-1 levels of genetic variants are not related to the MMP-1 (–1607) polymorphism.

To cite this article

Low level of matrix metalloproteinase-1 in patients with bladder cancer and the effect of MMP-1 polymorphism (-1607) on serum MMP-1 levels and the risk of bladder cancer

WCRJ 2018; 5 (3): e1132

Publication History

Submission date: 28 Jun 2018

Revised on: 04 Jul 2018

Accepted on: 27 Aug 2018

Published online: 20 Sep 2018